Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.26)
# 449
Out of 5,131 analysts
84
Total ratings
54.1%
Success rate
17.26%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $20.57 | +94.46% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $19.78 | +178.06% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $33.69 | +3.89% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $9.15 | +173.22% | 1 | Nov 20, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $40 | $31.66 | +26.34% | 1 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $64.64 | +23.76% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.92 | +102.70% | 1 | Sep 3, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $17.04 | +99.53% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $41.23 | +33.40% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $33.84 | -5.44% | 6 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $132.66 | +39.45% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $76.84 | -34.93% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $24.13 | +107.21% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $102.18 | +22.33% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $57.71 | +81.94% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $768.00 | +52.99% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $64.87 | +31.03% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $24.37 | +261.10% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $185.63 | +48.68% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.58 | +664.19% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $325.54 | -28.73% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $106.33 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $122.60 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.62 | -29.10% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.29 | +265.95% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $15.68 | +1,494.39% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.18 | +747.46% | 1 | Feb 14, 2018 |
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $20.57
Upside: +94.46%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $19.78
Upside: +178.06%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $33.69
Upside: +3.89%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $9.15
Upside: +173.22%
Upstream Bio
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $31.66
Upside: +26.34%
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $64.64
Upside: +23.76%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $5.92
Upside: +102.70%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $17.04
Upside: +99.53%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $41.23
Upside: +33.40%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $33.84
Upside: -5.44%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $132.66
Upside: +39.45%
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $76.84
Upside: -34.93%
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $24.13
Upside: +107.21%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $102.18
Upside: +22.33%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $57.71
Upside: +81.94%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $768.00
Upside: +52.99%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $64.87
Upside: +31.03%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $24.37
Upside: +261.10%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $185.63
Upside: +48.68%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.58
Upside: +664.19%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $325.54
Upside: -28.73%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $106.33
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $122.60
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.62
Upside: -29.10%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.29
Upside: +265.95%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $15.68
Upside: +1,494.39%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.18
Upside: +747.46%